Nothing Special   »   [go: up one dir, main page]

AU6276899A - Transplantation of neural cells for the treatment of ischemic damage due to stroke - Google Patents

Transplantation of neural cells for the treatment of ischemic damage due to stroke

Info

Publication number
AU6276899A
AU6276899A AU62768/99A AU6276899A AU6276899A AU 6276899 A AU6276899 A AU 6276899A AU 62768/99 A AU62768/99 A AU 62768/99A AU 6276899 A AU6276899 A AU 6276899A AU 6276899 A AU6276899 A AU 6276899A
Authority
AU
Australia
Prior art keywords
transplantation
stroke
treatment
damage due
neural cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU62768/99A
Inventor
Jonathan Dinsmore
Jerri Martin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Diacrin Inc
Original Assignee
Diacrin Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Diacrin Inc filed Critical Diacrin Inc
Publication of AU6276899A publication Critical patent/AU6276899A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0623—Stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Developmental Biology & Embryology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU62768/99A 1998-09-29 1999-09-29 Transplantation of neural cells for the treatment of ischemic damage due to stroke Abandoned AU6276899A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16327798A 1998-09-29 1998-09-29
US09163277 1998-09-29
PCT/US1999/022647 WO2000018414A1 (en) 1998-09-29 1999-09-29 Transplantation of neural cells for the treatment of ischemic damage due to stroke

Publications (1)

Publication Number Publication Date
AU6276899A true AU6276899A (en) 2000-04-17

Family

ID=22589274

Family Applications (1)

Application Number Title Priority Date Filing Date
AU62768/99A Abandoned AU6276899A (en) 1998-09-29 1999-09-29 Transplantation of neural cells for the treatment of ischemic damage due to stroke

Country Status (2)

Country Link
AU (1) AU6276899A (en)
WO (1) WO2000018414A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ614200A0 (en) * 2000-03-10 2000-03-30 Department Of Human Physiology, Flinders University School Of Medicine Method for treating chronic spinal cord injury
CA2494316A1 (en) * 2002-08-06 2004-02-12 Genvec, Inc. Improved injection system
AU2006205033A1 (en) * 2005-01-11 2006-07-20 Cognate Therapeutics, Inc. Bone marrow stromal cells for immunoprotection of transplanted neural stem cells
WO2007148098A2 (en) * 2006-06-21 2007-12-27 Cambridge Enterprise Limited Methods of producing and propagating neural precursor cells
GB0822246D0 (en) 2008-12-05 2009-01-14 Reneuron Ltd Composition
GB0902034D0 (en) 2009-02-06 2009-03-11 Reneuron Ltd Method

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2089582A1 (en) * 1990-08-15 1992-02-16 Richard P. Bunge Autotransplantation of schwann cells to promote nervous system repair
WO1995012982A1 (en) * 1993-11-09 1995-05-18 The Trustees Of The University Of Pennsylvania Compositions and methods for producing and using homogeneous neuronal cell transplants
US6432711B1 (en) * 1993-11-03 2002-08-13 Diacrin, Inc. Embryonic stem cells capable of differentiating into desired cell lines
CA2186528A1 (en) * 1994-03-31 1995-10-12 E. Michael Egan Genetically modified cells for use in transplantation
EP0752868A1 (en) * 1994-03-31 1997-01-15 Diacrin, Inc. Improved methods for transplantation using modified cells and t cell inhibitory agents
US5753505A (en) * 1995-07-06 1998-05-19 Emory University Neuronal progenitor cells and uses thereof
WO1997037671A1 (en) * 1996-04-10 1997-10-16 Diacrin, Inc. Method for providing pathogen-free porcine tissue suitable for human transplantation

Also Published As

Publication number Publication date
WO2000018414A1 (en) 2000-04-06

Similar Documents

Publication Publication Date Title
AU1075699A (en) Hybrid nanofibril matrices for use as tissue engineering devices
AU1725099A (en) Devices for cloaking transplanted cells
AU1943401A (en) An environmental chamber for the analysis of live cells
AU6263599A (en) Heterocyclic 2-substituted ketoamides useful for treating hair loss in mammals
EP0682107A3 (en) Method for the long term culturing of dermal papilla cells.
AU5994900A (en) Compounds for inhibiting diseases and preparing cells for transplantation
AU5854100A (en) Lithium cell
AU2448900A (en) Easy to remove overwrap
AU4861999A (en) Use of the first polar body chromosomes for the production of embryos
AU6992600A (en) Multispan girder
AU6276899A (en) Transplantation of neural cells for the treatment of ischemic damage due to stroke
AU3420700A (en) Arrangement of electrochemical cells
AU5485398A (en) Method for increasing the efficiency of photoelectro-chemical cells, and photoelectro-chemical cells realized according to said method
GB2309701B (en) Organic electrolyte composition
AUPO776697A0 (en) Method of increasing the iron content of plant cells
AU2021601A (en) Composition for the treatment of dandruff
AU7268000A (en) Method for quantization of the antiviral effect of antiviral active principles
AU6083898A (en) Method for the manufacture of photovoltaic cell
AU4387300A (en) Beehive
IL117470A0 (en) Sertoli cells as transplantation facilitator for cell transplantation
AU6006800A (en) Treating cells
AU4463700A (en) Transformed cells useful for the control of pests
GB9820776D0 (en) Imrovements to infrarec cells
AU3753500A (en) Methods of treating fibrinogen-related disorders
AU3452700A (en) Antibodies to placental protein 13

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase